The Portfolio Committee on Health has resolved to meet behind closed doors to consider its next step after the Department of Health failed to act on repeated warnings about a multibillion-rand antiretroviral (ARV) tender.
The committee’s decision followed a briefing from the Minister of Health, Dr Aaron Motsoaledi and senior officials from the Department of Health on a recent High Court judgment that set aside portions of the ARV tender process after finding serious flaws in the evaluation and awarding of contracts.
Opening the meeting, committee Chairperson, Ms Faith Muthambi, said that the issue is not only about procurement compliance but also access to treatment for millions of South Africans relying on the public healthcare system. “This is a matter of critical public importance because it concerns access to life-saving treatment for millions of South Africans who depend on the public health system. We expect a comprehensive update on the implications of the court judgment, the availability of medicines across provinces and the interventions being implemented to ensure uninterrupted access to treatment,” she said.
The department noted that it would not appeal the judgment and accepted the court’s findings. Officials acknowledged that aspects of the tender process would need to be revisited. They also advised committee members that although the department is not appealing the ruling, several affected companies have lodged applications for leave to appeal.
During the engagement after the briefing, committee members reminded the department about a meeting in February in which they had raised concerns about supplier capacity, common ownership structures, alleged collusion among bidders and the failure to conduct adequate due diligence. Many of those concerns have now been validated by the court, they said.
Committee member Ms Michele Clarke questioned how basic procurement safeguards could have failed so comprehensively. “If the department failed to verify licence requirements, local manufacturing claims and empowerment credentials, how can the committee have confidence in the integrity of the department’s other pharmaceutical tenders,” she said.
Committee member Dr Kgosi Letlape described the allegations as so serious that they warranted intervention beyond ordinary departmental investigations. “There seems to be elements of insider trading in this aspect, which is serious given the importance of ARVs in this country and that we have the largest burden of people living with HIV. We need something akin to a Madlanga-type commission to probe this matter comprehensively,” he said.
Committee member Ms Naledi Chirwa-Mpungose said the problem is not that the Minister did not know. “We told him. We gave him all the information. We raised the issue of common ownership, possible collusion and failures in due diligence. The problem is that the Minister failed to act,” said Ms Chirwa-Mpungose.
The committee refused accept the narrative of the Minister distancing himself from the debacle. “You knew on the 18th of February. It is on the record. We told you what was happening. You did nothing about it. The court had to act, and the Hawks had to act. Tell us what you did as Minister after finding out that corruption was at play,” Ms Chirwa-Mpungose asked.
The committee waw of the view that the Minister was misled by officials and that these officials – those who supplied incorrect information and were responsible for these contracts – must be held accountable.
Ms Muthambi said the court judgment had cast serious doubt on the credibility of some of the assurances Parliament received in the February meeting. “If the court did not rule otherwise, whatever we were told in February would have remained the gospel truth. That is the concern. We were assured of certain things, but the court is now saying something completely different.”
The Chairperson criticised what she described as a culture of compliance presentations that do not assist committee members in exercising their oversight responsibilities. “This thing of people just doing presentations for the sake of presenting and not telling us the truth is a problem. We cannot continue like this. Parliament cannot simply be expected to tick boxes while serious issues are unfolding.”
Ms Muthambi said the officials implicated in the issues being investigated should already have been subject to stronger corrective action. “By now these matters should have triggered immediate processes. The questions we are asking today are questions that should already have been answered through internal action.”
The committee is unhappy about the manner in which this matter has been handled. Millions of South Africans depend on these medicines, and the committee cannot sit back when serious allegations of misconduct, collusion and procurement failures continue to emerge.
The committee will meet in camera to consider to further deliberate on the issues and the concerns raised by members and possible recommendations arising from the matter.
Yoliswa Landu
19 November 2026

